Salute e Benessere

Electrolux Group to divest Memphis factory

The agreement includes a due diligence period before closing of the transaction, during which the buyer can terminate the contract. The agreed purchase price is USD 61m (approx. SEK 675m). The agreement includes a due diligence period before closing of the transaction, during which the buyer can terminate the contract. The agreed purchase price isUSD 61m(approx.SEK 675m ). The approximate gain ofUSD 50m(approx.SEK 550m ) from the divestment will be recorded as a non-recurring...
PR Newswire
21/09/2023

Assisted Reproductive Technology Market Size is Projected to Hit USD 63.88…

Assisted reproductive technology is a cumulative term given to the set of medical techniques used to address infertility. This technology primarily involves the manipulation of sperms, eggs, and embryos. Common ART procedures include in vitro fertilization (IVF), artificial insemination intracytoplasmic sperm injection (ICSI), surrogacy fertility treatments, gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). These procedures may involve the use of fertility drugs…
PR Newswire
21/09/2023

Yuyu Healthcare Conducts Global Promotion at Vitafoods Asia 2023

Yuyu Healthcare's CEO said, "For the first time in its history, Yuyu Healthcare will be operating a booth at an international event such as Vitafoods Asia 2023. It is a turning point for corporate growth and we plan to continue to find overseas customers in the future." Yuyu Healthcare's CEO said, "For the first time in its history, Yuyu Healthcare will be operating a booth at an international event such as Vitafoods Asia 2023. It is a turning point for corporate growth and we…
PR Newswire
21/09/2023

Mendus to present novel data supporting the broad potential of its proprietary…

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its lead clinical program vididencel at CICON23 – the International Cancer Immunotherapy Conference in Milan, Italy. The data further validate vididencel's proposed mechanism of action and demonstrate that immune responses triggered by the cell-based cancer vaccine in patients with Acute Myeloid...
Nasdaq GlobeNewswire
21/09/2023

New cell therapy facility enters fight against chronic diseases

"Cell therapies have the potential to take us from treating or managing the symptoms of chronic diseases to treating the disease itself, or even curing it with a one-off procedure," says Thomas H.R. Carlsen, CEO of the Novo Nordisk Foundation Cellerator. "Cell therapies have the potential to take us from treating or managing the symptoms of chronic diseases to treating the disease itself, or even curing it with a one-off procedure," saysThomas H.R. Carlsen, CEO of the Novo…
PR Newswire
21/09/2023

Latest Clinical Evidence Presented at APWCA's Wound Week™ 2023 Illustrates the…

"The evidence is irrefutable," says Dr. Thomas Serena, the Founder and Medical Director of The SerenaGroup®. "The importance of MolecuLight's point-of-care imaging of bacterial load as an essential tool for all wound care practitioners is again supported by the results of our 1,447 patient, multi-center study, "Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging". The use of MolecuLight…
PR Newswire
21/09/2023

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

Product sales more than doubled in the first half of 2023to €69.7 million compared to€33.3 million in the first half of 2022Driven by IXIARO ®and DUKORAL ®sales, both of which benefited from a continued recovery of the travel industry as well as from price increasesBringing total revenues to €73.7 million in the first half of 2023Strong cash position of €204.4 million as at June 30, 2023Excludes up to an additional $100 million made available...
Nasdaq GlobeNewswire
21/09/2023

Press release Biocartis Group NV: Biocartis 2023 half-year results webcast on 26…

PRESS RELEASE REGULATED INFORMATION 21 September 2023 , 07:00 CESTBIOCARTIS 2023 HALF-YEAR RESULTS WEBCAST ON 26 SEPTEMBER 2023Mechelen, Belgium,21 September 2023 –Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), will report its 2023 half-year results...
Nasdaq GlobeNewswire
21/09/2023

Electronic Health Records Market Size to Hit USD 52.98 Billion by 2027, With at…

However, electronic medical records implementation also comes with challenges, such as concerns about data security and privacy, the cost of system adoption, and the need for staff training. Despite these challenges, electronic health records have become a cornerstone of modern healthcare, facilitating improved patient care, clinical documentation, decision-making, and healthcare system efficiency. They play a critical role in the digital transformation of the healthcare industry, helping…
PR Newswire
21/09/2023

Intrahepatic Cholangiocarcinoma Market to Grow Rapidly During the Study Period…

Key Takeaways from the Intrahepatic Cholangiocarcinoma Market Report Key Takeaways from the Intrahepatic Cholangiocarcinoma Market Report Discover which therapies are expected to grab the major intrahepatic cholangiocarcinoma market share @Intrahepatic Cholangiocarcinoma Market Report Intrahepatic Cholangiocarcinoma Overview Intrahepatic cholangiocarcinoma, a rare and aggressive form of cancer, originates in the bile ducts within the liver. While the exact causes are not...
PR Newswire
20/09/2023

GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate…

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE ®trial in June 2023, paving the way to:a potential submission to the health authorities by Ipsen, and a potential first milestone met before the end of 2023, and if approved, commercialization would trigger further milestone payments and royalty paymentsGENFIT's leadership in ACLF is further strengthened, with now 5...
Nasdaq GlobeNewswire
20/09/2023

Casino Group: Update BP 2024-2028

Reminder of 2023 forecasts and communication on Groupe Casino's updated 2024-2028 business plan Paris, 20 September 2023Casino Group today posted a presentation on the company's website 1regarding the Group's updated 2024-2028 business plan.This new business plan is based on: The 2024-2028 business plan published on June 26, 2023, the reforecast for the 2023 financial year (unchanged) 2, which has already been the subject of a Group publication dated July 27, 2023, the review...
Nasdaq GlobeNewswire
20/09/2023

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to…

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $ 231 million in clinical, regulatory and commercial milestone payments in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea.Pending regulatory approvals, Hepalys...
Nasdaq GlobeNewswire
20/09/2023

Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood…

New York and Bagsværd, 20 September 2023– Novo Nordisk and UNICEF today announced an extension of their long-term partnership to help prevent global childhood overweight and obesity - a public health crisis that affects millions of children worldwide. Over the next three years Novo Nordisk will commit 8 million US dollars to scale and accelerate efforts to create healthier environments for children through policy implementation and innovations that enable children to eat well, play and be...
Nasdaq GlobeNewswire
20/09/2023

Diana Bracco: "Artificial Intelligence will assist radiologists in making…

The symposium included three sessions with important international keynote speakers, and concluded with final remarks by Anna Maria Bernini, Minister of University and Research. The first one, which looked at the new capacities of Artificial Intelligence in drug discovery, omics sciences, and pharmaceutical manufacturing, highlighted how AI is destined to play a significant role in many aspects of medicine and the healthcare industry. Specifically, AI will: accelerate the speed of development of…
PR Newswire
20/09/2023

The Non-viral Transfection Reagents and Systems Market is projected to grow at…

Non-viral transfection, owing to its multiple benefits, has emerged as a promising alternative for conventional transfection approaches. Advantages offered by this technique include shorter transfection timelines, higher biological efficiency, reduced toxicity levels and versatile nucleic acid delivery. In fact, driven by the rising interest in research and development activities and the growing demand for non-viral transfection-based products, the non-viral transfection reagents and systems…
PR Newswire
20/09/2023

Pixium Vision announces the completion of the reverse stock split of its shares…

Pixium Vision announces the completion of thereverse stock split of its shares on the basis of 1 new share for 50 existing shares and the start of trading of the shares resulting afterthe completion of the reverse split as of September 21, 2023 Reverse stock split through the exchange of 50 existing shares for1 new share First trading day for post-reverse stock split shares is September 21, 2023Resumption of the right to...
Nasdaq GlobeNewswire
20/09/2023

IBA – Transparency Notification

IBA – TRANSPARENCY NOTIFICATION(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, September 20th, 2023 18:00 Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major...
Nasdaq GlobeNewswire
20/09/2023

The Teledentistry Market Is Projected To Reach $1.78 Billion In 2023, With…

Oral Disease Burden Oral Disease Burden Oral diseases, including dental caries, periodontal disease, and oral cancer, impose a significant health and economic burden worldwide. The World Health Organization (WHO) estimated that nearly 2.5 billion people globally suffer from various forms of oral diseases. This burden translates into annual direct costs of approximatelyUS$ 387 billionand indirect costs of anotherUS$ 323 billion. Notably, dental caries remains the most prevalent...
PR Newswire
20/09/2023

Guerbet: 2023 half-year results

Half-year results 2023Acceleration of activityHalf-year revenue: €378.6 million, up 2.8% at CER 1 Strong acceleration of activity in the second quarter, up 6.7% at CERProfitability in line with expectationsEBITDA for the first half-year: €45.9 million, compared to €50.5 million one year earlierThe restated EBITDA margin 2amounted to 12.7% of revenue2023 objectives confirmedRevenue: expected growth of more than 5% on a like-for-like basis and at CER...
Nasdaq GlobeNewswire
20/09/2023

On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

Accompanying its oral presentation at the 2023 ASCO Annual Meeting, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has unveiled impressive results from its Phase 2 trial of a drug for metastatic breast cancer, offering a promising avenue for those with the disease and catching the eye of RBC Capital. Accompanying its oral presentation at the 2023 ASCO Annual Meeting,Oncolytics Biotech Inc.(NASDAQ: ONCY) (TSX: ONC) has unveiled impressive results from its Phase 2 trial of a drug for...
PR Newswire
20/09/2023

AI in Genomics Market Size to Grow USD 9,859.7 Million by 2031 Registering a…

Get Free Sample Research Report: https://reports.valuates.com/request/sample/ALLI-Manu-1D78/AI_in_Genomics_Market Get Free Sample Research Report:https://reports.valuates.com/request/sample/ALLI-Manu-1D78/AI_in_Genomics_Market Major Factors Driving the Growth of AI in Genomics Market: The demand for cost and time management in drug research and development, rising public and private investments in genomics AI, and the acceptance of AI solutions in precision medicine are the...
PR Newswire
20/09/2023

European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the…

"We have long known that patients living with metastatic breast cancer need effective and tolerable options which treat their disease while enabling them to focus on the things that matter to them," said Elcin Barker Ergun, CEO of the Menarini Group. "We are proud of delivering a new breast cancer treatment that offers efficacy in a once-daily pill and represents the first innovation in endocrine therapy in nearly two decades; we are also incredibly grateful for the support of the…
PR Newswire
20/09/2023

Incontinence Care Products (ICP) Market worth $16.5 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71950351 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71950351 Browse in-depth TOC on "Incontinence Care Products (ICP) Market" 209 - Tables 44 - Figures 225 - Pages Incontinence Care Products (ICP) Market Scope: In 2022, the absorbable segment held the largest share of the incontinence care products market, by product type segment...
PR Newswire
20/09/2023
Altri  Comunicati